3期临床-话题@MedSci

#3期临床#

90篇内容 | 2811人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1911252, encodeId=f8d01911252ca, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=长效生长激素Somatrogon治疗生长激素缺乏症儿童，日本3期临床成功, objectType=article, longId=195624, objectId=fdb21956248b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdb21956248b, replyNumber=0, likeNumber=103, createdTime=2021-03-02, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdb21956248b, moduleTitle=长效生长激素Somatrogon治疗生长激素缺乏症儿童，日本3期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdb21956248b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911259, encodeId=1eac191125908, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐, objectType=article, longId=202790, objectId=00a7202e904b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a7202e904b, replyNumber=0, likeNumber=73, createdTime=2021-07-27, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a7202e904b, moduleTitle=头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00a7202e904b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911258, encodeId=b3cd191125854, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=强生新冠疫苗3期临床试验由于参与者出现不明疾病而暂停, objectType=article, longId=202057, objectId=2cdb20205eb3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cdb20205eb3, replyNumber=0, likeNumber=62, createdTime=2020-12-12, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cdb20205eb3, moduleTitle=强生新冠疫苗3期临床试验由于参与者出现不明疾病而暂停, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cdb20205eb3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911260, encodeId=4bff191126007, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast, objectType=article, longId=202961, objectId=601d202961a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=601d202961a3, replyNumber=0, likeNumber=60, createdTime=2021-10-01, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=601d202961a3, moduleTitle=BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=601d202961a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911256, encodeId=7e63191125609, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=中国患者数据来了！本土卵巢癌PARP抑制剂3期临床研究成果闪耀ESMO, objectType=article, longId=200959, objectId=4aa820095905, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4aa820095905, replyNumber=0, likeNumber=93, createdTime=2020-12-17, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4aa820095905, moduleTitle=中国患者数据来了！本土卵巢癌PARP抑制剂3期临床研究成果闪耀ESMO, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4aa820095905)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911262, encodeId=3cc019112624d, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Eur J Cancer：雄激素剥夺疗法联合放疗治疗中危前列腺癌的3期临床试验结果, objectType=article, longId=204317, objectId=89b720431e86, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89b720431e86, replyNumber=0, likeNumber=74, createdTime=2021-04-11, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89b720431e86, moduleTitle=Eur J Cancer：雄激素剥夺疗法联合放疗治疗中危前列腺癌的3期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89b720431e86)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911257, encodeId=7861191125eb2, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=PD-1单抗Opdivo新辅助治疗非小细胞肺癌，3期临床获益, objectType=article, longId=201929, objectId=558820192924, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=558820192924, replyNumber=0, likeNumber=59, createdTime=2021-04-03, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=558820192924, moduleTitle=PD-1单抗Opdivo新辅助治疗非小细胞肺癌，3期临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=558820192924)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911251, encodeId=5ab6191125119, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=3期临床研究证实，促性腺激素释放激素（GnRH）受体拮抗剂Relugolix 显着减轻子宫内膜异位症女性的疼痛, objectType=article, longId=192962, objectId=cdb5192962b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdb5192962b6, replyNumber=0, likeNumber=72, createdTime=2020-05-23, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdb5192962b6, moduleTitle=3期临床研究证实，促性腺激素释放激素（GnRH）受体拮抗剂Relugolix 显着减轻子宫内膜异位症女性的疼痛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdb5192962b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911249, encodeId=6284191124954, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Keytruda针对经典霍奇金淋巴瘤的验证性3期临床试验达到了主要终点, objectType=article, longId=189427, objectId=cb2d18942e7b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb2d18942e7b, replyNumber=0, likeNumber=0, createdTime=2020-05-29, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb2d18942e7b, moduleTitle=Keytruda针对经典霍奇金淋巴瘤的验证性3期临床试验达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb2d18942e7b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911253, encodeId=f5d819112530b, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, objectType=article, longId=195839, objectId=0f4c19583900, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f4c19583900, replyNumber=0, likeNumber=61, createdTime=2021-01-19, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f4c19583900, moduleTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f4c19583900)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911248, encodeId=e50f191124828, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果, objectType=article, longId=187166, objectId=2f3218e16658, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f3218e16658, replyNumber=0, likeNumber=74, createdTime=2020-04-13, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f3218e16658, moduleTitle=礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f3218e16658)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911254, encodeId=262e191125459, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=三功能双特异性抗体Catumaxomab治疗腹膜癌，获得NMPA授权开始全球性3期临床试验, objectType=article, longId=197631, objectId=9f1c19e631bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f1c19e631bf, replyNumber=0, likeNumber=62, createdTime=2020-08-30, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f1c19e631bf, moduleTitle=三功能双特异性抗体Catumaxomab治疗腹膜癌，获得NMPA授权开始全球性3期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f1c19e631bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911250, encodeId=689919112502c, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=3期临床新数据证明：THR-β激动剂Resmetirom可显着降低NASH患者的肝脏脂肪和纤维化程度, objectType=article, longId=192378, objectId=5c501923e835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c501923e835, replyNumber=0, likeNumber=65, createdTime=2021-01-04, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c501923e835, moduleTitle=3期临床新数据证明：THR-β激动剂Resmetirom可显着降低NASH患者的肝脏脂肪和纤维化程度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c501923e835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911246, encodeId=2a4d191124691, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=中国糖尿病创新药Dorzagliatin达到3期临床主要疗效终点，可降低HbA1c 1.07%, objectType=article, longId=182879, objectId=7aba1828e9ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7aba1828e9ca, replyNumber=0, likeNumber=75, createdTime=2020-09-30, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7aba1828e9ca, moduleTitle=中国糖尿病创新药Dorzagliatin达到3期临床主要疗效终点，可降低HbA1c 1.07%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7aba1828e9ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911242, encodeId=72db1911242d8, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=GSK抗GM-CSF单抗otilimab治疗类风湿性关节炎正在开展3期临床研究, objectType=article, longId=174900, objectId=d1021e49006a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1021e49006a, replyNumber=0, likeNumber=78, createdTime=2020-01-21, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1021e49006a, moduleTitle=GSK抗GM-CSF单抗otilimab治疗类风湿性关节炎正在开展3期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1021e49006a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911240, encodeId=40e819112405f, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=武田的蛋白酶抑制剂Ninlaro治疗系统性轻链淀粉样变性患者的3期临床研究失败告终, objectType=article, longId=167837, objectId=497116e837ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=497116e837ab, replyNumber=0, likeNumber=86, createdTime=2020-02-28, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=497116e837ab, moduleTitle=武田的蛋白酶抑制剂Ninlaro治疗系统性轻链淀粉样变性患者的3期临床研究失败告终, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=497116e837ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911244, encodeId=da101911244c7, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=OPKO和辉瑞宣布长效化生长激素GENOTROPIN治疗生长激素缺乏症儿童的3期临床成功, objectType=article, longId=181709, objectId=aafc181e09cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aafc181e09cb, replyNumber=0, likeNumber=110, createdTime=2020-02-05, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aafc181e09cb, moduleTitle=OPKO和辉瑞宣布长效化生长激素GENOTROPIN治疗生长激素缺乏症儿童的3期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aafc181e09cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911247, encodeId=9e65191124ec8, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Ann Rheum Dis：两项使用ixekizumab治疗活动性放射学axSpA 3期临床试验的疗效和安全性（COAST-V和COAST-W）, objectType=article, longId=183366, objectId=0e97183366d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e97183366d9, replyNumber=0, likeNumber=70, createdTime=2020-01-24, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e97183366d9, moduleTitle=Ann Rheum Dis：两项使用ixekizumab治疗活动性放射学axSpA 3期临床试验的疗效和安全性（COAST-V和COAST-W）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e97183366d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911239, encodeId=7d8c191123975, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Vertex新的三联组合治疗囊性纤维化，3期临床大获成功, objectType=article, longId=167517, objectId=7e0916e517c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e0916e517c8, replyNumber=0, likeNumber=118, createdTime=2019-07-01, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e0916e517c8, moduleTitle=Vertex新的三联组合治疗囊性纤维化，3期临床大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e0916e517c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911236, encodeId=45f119112369c, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Eli Lilly的Cyramza作为转移性非小细胞肺癌的一线治疗达到了3期临床试验的主要终点, objectType=article, longId=162242, objectId=fef6162242d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fef6162242d9, replyNumber=0, likeNumber=55, createdTime=2019-11-09, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fef6162242d9, moduleTitle=Eli Lilly的Cyramza作为转移性非小细胞肺癌的一线治疗达到了3期临床试验的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fef6162242d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

3期临床

2020-05-29

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

长效生长激素Somatrogon治疗生长激素缺乏症儿童，日本3期临床成功

2021-03-02

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐

2021-07-27

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

强生新冠疫苗3期临床试验由于参与者出现不明疾病而暂停

2020-12-12

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast

2021-10-01

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

中国患者数据来了！本土卵巢癌PARP抑制剂3期临床研究成果闪耀ESMO

2020-12-17

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Eur J Cancer：雄激素剥夺疗法联合放疗治疗中危前列腺癌的3期临床试验结果

2021-04-11

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

PD-1单抗Opdivo新辅助治疗非小细胞肺癌，3期临床获益

2021-04-03

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

3期临床研究证实，促性腺激素释放激素（GnRH）受体拮抗剂Relugolix 显着减轻子宫内膜异位症女性的疼痛

2020-05-23

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Keytruda针对经典霍奇金淋巴瘤的验证性3期临床试验达到了主要终点

2020-05-29

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab

2021-01-19

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果

2020-04-13

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

三功能双特异性抗体Catumaxomab治疗腹膜癌，获得NMPA授权开始全球性3期临床试验

2020-08-30

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

3期临床新数据证明：THR-β激动剂Resmetirom可显着降低NASH患者的肝脏脂肪和纤维化程度

2021-01-04

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

中国糖尿病创新药Dorzagliatin达到3期临床主要疗效终点，可降低HbA1c 1.07%

2020-09-30

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

GSK抗GM-CSF单抗otilimab治疗类风湿性关节炎正在开展3期临床研究

2020-01-21

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

武田的蛋白酶抑制剂Ninlaro治疗系统性轻链淀粉样变性患者的3期临床研究失败告终

2020-02-28

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

OPKO和辉瑞宣布长效化生长激素GENOTROPIN治疗生长激素缺乏症儿童的3期临床成功

2020-02-05

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Ann Rheum Dis：两项使用ixekizumab治疗活动性放射学axSpA 3期临床试验的疗效和安全性（COAST-V和COAST-W）

2020-01-24

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Vertex新的三联组合治疗囊性纤维化，3期临床大获成功

2019-07-01

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Eli Lilly的Cyramza作为转移性非小细胞肺癌的一线治疗达到了3期临床试验的主要终点

2019-11-09

科室
- - 订阅+
  - 更多科室
工具
服务